36204-76-9

Usage

Uses

Used in Pharmaceutical Industry:
3-Amino-N-methylpyrazine-2-carboxamide is used as a reactant in the synthesis of triazole derivatives that are known to inhibit eosinophilia. Eosinophilia is a condition characterized by an abnormally high number of eosinophils, a type of white blood cell, in the body. These triazole derivatives can be used as potential therapeutic agents for treating eosinophilia and related disorders.

Upstream product

• 16298-03-6 Methyl 3-amino-2-pyrazinecarboxylate 
• 74-89-5 methylamine 
• 5424-01-1 3-aminopyrazinoic acid 
• 593-51-1 methylamine hydrochloride 

Relevant academic research and scientific papers

INHIBITORS OF FOCAL ADHESION KINASE

The invention provides inhibitors of focal adhesion kinase, an enzyme involved in the attachment of the cytoskeleton of a cell to an extracellular matrix, which has been implicated in processes such as cell migration, cell proliferation, and cell survival. The inhibitors are derivatives of a 5-substituted 2,4-diaminopyridine wherein the substituents are as defined herein. The invention also provides a method of using the inhibitors in treatment of cancer, and methods of preparation of the inhibitors by use of coupling reactions.

Synthesis and pharmacological activity of triazole derivatives inhibiting eosinophilia

In order to develop novel antiasthmatic agents based on a new mechanism of action, a series of 3-substituted 5-amino-1- [(methylamino)(thiocarbonyl)]-1H-1,2,4-triazole derivatives were synthesized and evaluated in a model in which eosinophilia was induced in the airway through intravenous (iv) injection of Sephadex particles on days 0, 2, and 5. After screening of several hundred derivatives, we finally identified the highly potent eosinophilia inhibitor 5-amino-3-(4-chlorophenyl)-1- [(methylamino)(thiocarbonyl)]-1H-triazole (23c, GCC-AP0341), which had ID50 values of 0.3 and 0.07 mg/kg when administered orally (os) and intraperitoneally (ip), respectively. This compound showed complete inhibition of the hypersensitivity induced by ascaris inhalation at an ip dose of 1 mg/kg as well as low toxicity, with an LD50 value of >2.0 g/kg in mice. Extensive study of its mechanism of action revealed that 23c inhibited eosinophil survival induced by interleukin-5 (IL-5), but had little or no effect on leukotriene D4 (LTD4) or platelet-activating factor (PAF)- induced responses. Taken together, these results suggest 23c as a novel candidate for the treatment of chronic asthma. Further studies are now underway.